Abbott Laboratories (ABT) : 10 brokerage houses believe that Abbott Laboratories (ABT) is a Strong Buy at current levels. 2 Analyst considers the fundamentals to be worthy of a Buy recommendation. 4 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Abbott Laboratories (ABT). Zacks Investment Research suggests a Buy with a rank of 2.The median of all the 16 Wall Street Analysts endorse the stock as a Buy with a rating of 1.63.
Abbott Laboratories (ABT) has been rated by 11 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $50 and the lowest price target forecast is $45. The average forecast of all the analysts is $47.55 and the expected standard deviation is $1.75.
Abbott Laboratories (NYSE:ABT): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $39.27 and $39.25 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $40.88. The buying momentum continued till the end and the stock did not give up its gains. It closed at $40.83, notching a gain of 3.52% for the day. The total traded volume was 13,177,175 . The stock had closed at $39.44 on the previous day.
Also, In a research note released to the investors, Edward Jones upgrades its rating on Abbott Laboratories (NYSE:ABT).The analysts at the brokerage house have a current rating of Buy on the shares. Earlier, the shares were rated a Hold by the brokerage firm. The rating by the firm was issued on June 21, 2016. The company shares have dropped -19.92% from its 1 Year high price. On Jul 23, 2015, the shares registered one year high at $51.74 and the one year low was seen on Jan 28, 2016. The 50-Day Moving Average price is $38.40 and the 200 Day Moving Average price is recorded at $40.02.
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products.